Incidence of cancer after immunosuppressive treatment for heart transplantation
- PMID: 15979322
- DOI: 10.1016/j.critrevonc.2005.03.013
Incidence of cancer after immunosuppressive treatment for heart transplantation
Abstract
Prolonged or intensive immunosuppressive therapy used after organ transplantation is complicated by an increased incidence of cancer. Striking differences in incidence are observed in heart and heart-lung transplant recipients when compared with renal transplant patients. The most significant increase was in the incidence of lymphomas in cardiac versus renal patients. Moreover, a two-fold greater increase of all neoplasms was found in cardiac recipients, with nearly a six-fold increase in visceral tumors. Several factors may account for these differences. In cardiac allograft recipients, intensive immunosuppression is frequently used to reverse acute rejection and the highest number of cardiac transplants was performed in the era of polypharmacy, usually consisting of triple therapy.
Similar articles
-
Cancer incidence after immunosuppressive treatment following kidney transplantation.Crit Rev Oncol Hematol. 2005 Oct;56(1):71-85. doi: 10.1016/j.critrevonc.2004.11.010. Crit Rev Oncol Hematol. 2005. PMID: 15978827 Review.
-
Tumors after renal and cardiac transplantation.Hematol Oncol Clin North Am. 1993 Apr;7(2):431-45. Hematol Oncol Clin North Am. 1993. PMID: 8468275 Review.
-
Non-melanoma skin cancer and its risk factors in an Austrian population of heart transplant recipients receiving induction therapy.Int J Dermatol. 2008 Sep;47(9):918-25. doi: 10.1111/j.1365-4632.2008.03711.x. Int J Dermatol. 2008. PMID: 18937654
-
Solid tumors after heart transplantation: lethality of lung cancer.Ann Thorac Surg. 1995 Dec;60(6):1623-6. doi: 10.1016/0003-4975(95)00120-4. Ann Thorac Surg. 1995. PMID: 8787454
-
Comparison of the incidence of de novo solid malignancies after heart transplantation to that in the general population.Am J Cardiol. 2009 Feb 15;103(4):562-6. doi: 10.1016/j.amjcard.2008.10.026. Epub 2008 Dec 26. Am J Cardiol. 2009. PMID: 19195521
Cited by
-
Introduction to the use of belatacept: a fusion protein for the prevention of posttransplant kidney rejection.Biologics. 2012;6:355-62. doi: 10.2147/BTT.S27565. Epub 2012 Oct 4. Biologics. 2012. PMID: 23055693 Free PMC article.
-
Optimal sampling time-point for cyclosporin A concentration monitoring in heart transplant recipients.Exp Ther Med. 2018 Nov;16(5):4265-4270. doi: 10.3892/etm.2018.6711. Epub 2018 Sep 10. Exp Ther Med. 2018. PMID: 30402164 Free PMC article.
-
Metastatic Lung Adenocarcinoma Harboring an EGFR-Activating Mutation in a Heart Transplant Recipient.J Glob Oncol. 2018 Sep;4:1-4. doi: 10.1200/JGO.17.00029. Epub 2017 Jun 30. J Glob Oncol. 2018. PMID: 30241181 Free PMC article. No abstract available.
-
Are patients with inflammatory eye disease treated with systemic immunosuppressive therapy at increased risk of malignancy?J Ophthalmic Inflamm Infect. 2013 May 31;3(1):48. doi: 10.1186/1869-5760-3-48. J Ophthalmic Inflamm Infect. 2013. PMID: 23724805 Free PMC article.
-
Oral health complications after a heart transplant: a review.Br Dent J. 2020 Feb;228(3):177-182. doi: 10.1038/s41415-020-1244-0. Br Dent J. 2020. PMID: 32060460 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical